Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging drugs for schizophrenia: an update
Luisa-Sophie Köster, Maren Carbon, Christoph U. Correll
Expert Opinion on Emerging Drugs (2014) Vol. 19, Iss. 4, pp. 511-531
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Schizophrenia
René S. Kahn, Iris E. Sommer, Robin M. Murray, et al.
Nature Reviews Disease Primers (2015) Vol. 1, Iss. 1
Closed Access | Times Cited: 900
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH)
Brendon Stubbs, Davy Vancampfort, Mats Hallgren, et al.
European Psychiatry (2018) Vol. 54, pp. 124-144
Open Access | Times Cited: 538
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Peter Manu, Lorena Dima, Matisyahu Shulman, et al.
Acta Psychiatrica Scandinavica (2015) Vol. 132, Iss. 2, pp. 97-108
Closed Access | Times Cited: 253
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
Maren Carbon, Christoph U. Correll
CNS Spectrums (2014) Vol. 19, Iss. S1, pp. 35-53
Closed Access | Times Cited: 214
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Peter Haddad, Christoph U. Correll
Therapeutic Advances in Psychopharmacology (2018) Vol. 8, Iss. 11, pp. 303-318
Open Access | Times Cited: 199
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, et al.
CNS Spectrums (2019) Vol. 24, Iss. S1, pp. 38-69
Open Access | Times Cited: 103
Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia
Britta Galling, Jeffrey A. Vernon, Anne Katrine Pagsberg, et al.
Acta Psychiatrica Scandinavica (2018) Vol. 137, Iss. 3, pp. 187-205
Closed Access | Times Cited: 72
In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide
Michael J. Majcher, Ali Babar, Andrew Lofts, et al.
Journal of Controlled Release (2020) Vol. 330, pp. 738-752
Closed Access | Times Cited: 59
QSPR Analysis of Drugs for Treatment of Schizophrenia Using Topological Indices
Xiujun Zhang, Muhammad Jawwad Saif, Nazeran Idrees, et al.
ACS Omega (2023) Vol. 8, Iss. 44, pp. 41417-41426
Open Access | Times Cited: 18
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis, Christoph U. Correll
Expert Review of Neurotherapeutics (2016) Vol. 16, Iss. 6, pp. 601-614
Open Access | Times Cited: 57
Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists
Xin Chen, John D. McCorvy, Matthew G. Fischer, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 23, pp. 10601-10618
Open Access | Times Cited: 46
Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder
Marc Cantillon, Arul Prakash, Ajay Alexander, et al.
Schizophrenia Research (2017) Vol. 189, pp. 126-133
Closed Access | Times Cited: 42
Eccentric indices based QSPR evaluation of drugs for schizophrenia treatment
Muneeba Mansha, Sarfraz Ahmad, Zahid Raza
Heliyon (2025) Vol. 11, Iss. 2, pp. e42222-e42222
Open Access
Treatment of clozapine-associated weight gain: a systematic review
Zachary Whitney, Ric M. Procyshyn, Diane Fredrikson, et al.
European Journal of Clinical Pharmacology (2015) Vol. 71, Iss. 4, pp. 389-401
Closed Access | Times Cited: 40
Glutamatergic agents for schizophrenia: current evidence and perspectives
Mathias Zink, Christoph U. Correll
Expert Review of Clinical Pharmacology (2015) Vol. 8, Iss. 3, pp. 335-352
Closed Access | Times Cited: 33
Cognitive impairment in schizophrenia: the great unmet need
Ralph Aquila, Leslie Citrome
CNS Spectrums (2015) Vol. 20, Iss. S1, pp. 32-40
Closed Access | Times Cited: 32
Sleep deprivation as an experimental model system for psychosis: Effects on smooth pursuit, prosaccades, and antisaccades
Inga Meyhöfer, Veena Kumari, Antje Hill, et al.
Journal of Psychopharmacology (2016) Vol. 31, Iss. 4, pp. 418-433
Closed Access | Times Cited: 30
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Ricardo P. Garay, Leslie Citrome, Ludovic Samalin, et al.
Expert Opinion on Pharmacotherapy (2016) Vol. 17, Iss. 7, pp. 921-936
Closed Access | Times Cited: 28
RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, et al.
Behavioural Brain Research (2017) Vol. 332, pp. 180-199
Closed Access | Times Cited: 26
The brief negative symptom scale (BNSS): Sensitivity to treatment effects
Brian Kirkpatrick, Jay Saoud, Gregory P. Strauss, et al.
Schizophrenia Research (2017) Vol. 197, pp. 269-273
Closed Access | Times Cited: 25
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.
MacEwan Jp, Seth A. Seabury, Aigbogun Ms, et al.
PubMed (2016) Vol. 13, Iss. 7-8, pp. 17-25
Closed Access | Times Cited: 20
A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
Meng di Hou, Viviana Santoro, Andrea Biondi, et al.
Journal of Psychiatry and Neuroscience (2021) Vol. 46, Iss. 6, pp. E675-E701
Open Access | Times Cited: 16
Dysregulation of auditory neuroplasticity in schizophrenia
Patrice Voss, Maryse E. Thomas, Gerson D. Guercio, et al.
Schizophrenia Research (2018) Vol. 207, pp. 3-11
Closed Access | Times Cited: 20
Investigational dopamine antagonists for the treatment of schizophrenia
Sheng‐Min Wang, Hans‐Jürgen Möller, Soo-Jung Lee, et al.
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 6, pp. 687-698
Closed Access | Times Cited: 17
Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?
Fang Fang, Zuowei Wang, Renrong Wu, et al.
Expert Review of Neurotherapeutics (2016) Vol. 17, Iss. 4, pp. 407-418
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top